GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Earnings per Share (Diluted)

CATX (Perspective Therapeutics) Earnings per Share (Diluted) : $-1.25 (TTM As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Earnings per Share (Diluted)?

Perspective Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was $-0.25. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.25.

Perspective Therapeutics's EPS (Basic) for the three months ended in Mar. 2025 was $-0.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.25.

Perspective Therapeutics's EPS without NRI for the three months ended in Mar. 2025 was $-0.25. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.92.

During the past 3 years, the average EPS without NRIGrowth Rate was -42.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.40% per year.

During the past 13 years, Perspective Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 67.80% per year. The lowest was -278.00% per year. And the median was 23.20% per year.


Perspective Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Perspective Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Earnings per Share (Diluted) Chart

Perspective Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.50 -0.30 -0.50 -1.74 -1.23

Perspective Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.18 -0.21 -0.61 -0.25

Competitive Comparison of Perspective Therapeutics's Earnings per Share (Diluted)

For the Medical Devices subindustry, Perspective Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's PE Ratio falls into.


;
;

Perspective Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Perspective Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-79.279-0)/64.425
=-1.23

Perspective Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2025 is calculated as

Diluted Earnings Per Share (Q: Mar. 2025 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-18.177-0)/72.357
=-0.25

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Perspective Therapeutics  (AMEX:CATX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Perspective Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics Business Description

Traded in Other Exchanges
Address
2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Executives
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354